API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Estradiol Valerate Injection USP is indicated (i) in the treatment of vasomotor symptoms associated with menopause (ii) in the management of hormonal imbalances due to castration or primary ovarian failure (iii) in the treatment of androgen-dependent carcinoma of the prostate.
Lead Product(s): Estradiol Valerate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021